Kyowa Kirin Co., Ltd. (TYO:4151)
2,579.50
-33.00 (-1.26%)
Aug 14, 2026, 3:30 PM JST
Kyowa Kirin Revenue
Kyowa Kirin had revenue of 145.16B JPY in the quarter ending June 30, 2026, with 15.27% growth. This brings the company's revenue in the last twelve months to 529.80B, up 7.41% year-over-year. In the year 2025, Kyowa Kirin had annual revenue of 496.83B with 0.26% growth.
Revenue (ttm)
529.80B
Revenue Growth
+7.41%
P/S Ratio
2.55
Revenue / Employee
102.42M
Employees
5,173
Market Cap
1.35T
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 496.83B | 1.27B | 0.26% |
| Dec 31, 2024 | 495.56B | 53.33B | 12.06% |
| Dec 31, 2023 | 442.23B | 43.86B | 11.01% |
| Dec 31, 2022 | 398.37B | 46.13B | 13.09% |
| Dec 31, 2021 | 352.25B | 33.89B | 10.65% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Otsuka Holdings | 2.62T |
| Astellas Pharma | 2.27T |
| Daiichi Sankyo Company | 2.22T |
| Chugai Pharmaceutical | 1.34T |
| Ono Pharmaceutical | 504.41B |
| Santen Pharmaceutical | 291.84B |
| JCR Pharmaceuticals | 41.45B |
| Perseus Proteomics | 135.00M |
Kyowa Kirin News
- 12 days ago - Kyowa Kirin Quarterly report: Q2 2026 - Filings
- 12 days ago - Kyowa Kirin Slides: Q2 2026 - Filings
- 7 weeks ago - The XLH Network and Kyowa Kirin Launch the XLH Community Guidebook to Help People Navigate Lifelong Journey with XLH - GlobeNewsWire
- 2 months ago - Kyowa Kirin to Present New Complementary Evidence Further Defining Clinical Utility of Mogamulizumab in Cutaneous T-Cell Lymphoma at 2026 WCCL - GlobeNewsWire
- 3 months ago - Kura, Kyowa Kirin to present updated frontline data from Phase 1 KOMET-007 trial - TheFly
- 3 months ago - Kyowa Kirin Quarterly report: Q1 2026 - Filings
- 3 months ago - Kyowa Kirin Slides: Q1 2026 - Filings
- 5 months ago - Kyowa Kirin downgraded to Sell from Buy at Citi - TheFly